Biopharma

All articles by Biopharma

Gilead Sciences brings on Omnicom to handle HIV portfolio
Gilead Sciences brings on Omnicom to handle HIV portfolio
Diana Bradley
May 17, 2024
8:00 am

BCW was the incumbent on the account.

Moderna’s Coffee Break Science social media series brews up biopharma buzz
Moderna’s Coffee Break Science social media series brews up biopharma buzz
Jack O'Brien
May 16, 2024
4:14 pm

The social media series is Moderna’s way of demystifying biology ahead of the fall vaccination season.

Biopharma M&A activity jumped 71% in Q1 2024
Biopharma M&A activity jumped 71% in Q1 2024
Lecia Bushak
May 16, 2024
10:19 am

Following a downturn in M&A activity during 2022 and 2023, the biopharma industry is increasing its level of dealmaking.

Cybin CEO on FDA breakthrough designation for psychedelic drug treating MDD
Cybin CEO on FDA breakthrough designation for psychedelic drug treating MDD
Jack O'Brien
March 27, 2024
12:50 pm

What does Cybin’s regulatory momentum and significant financial backing mean for the broader psychedelics space?

BridgeBio sells partial rights to dwarfism drug for $100M
BridgeBio sells partial rights to dwarfism drug for $100M
Marc Iskowitz
February 8, 2024
4:05 pm

The upfront payment pads BridgeBio’s balance sheet as the company gears up for the anticipated launch of another drug, ATTR-CM med acoramidas.

Stakes are high as biopharma gathers for JPM
Stakes are high as biopharma gathers for JPM
Marc Iskowitz
January 5, 2024
4:25 pm

2023 was a bad year for deal-making. Considering the headwinds, will 2024 be better? Here are some key questions as the JPMorgan Healthcare Conference gets underway.

Dyne Therapeutics’ Duchenne muscular dystrophy treatment shows promise
Dyne Therapeutics’ Duchenne muscular dystrophy treatment shows promise
Lecia Bushak
January 3, 2024
5:01 pm

Dyne released promising new data on its Duchenne muscular dystrophy drug, DYNE-251, as well as its myotonic dystrophy type 1 treatment DYNE-101.

Lilly expands radiopharmaceutical portfolio with $1.4B Point Biopharma deal
Lilly expands radiopharmaceutical portfolio with $1.4B Point Biopharma deal
Jack O'Brien
October 3, 2023
11:24 am

The transaction has been approved by the board of directors at both companies and Lilly said it expects the deal to close near the end of the year.

Rentschler Biopharma hires Benedikt von Braunmuehl as CEO
Rentschler Biopharma hires Benedikt von Braunmuehl as CEO
Lecia Bushak
September 19, 2023
1:27 pm

Rentschler Biopharma also brought on Tom Roberts to be president and GM, U.S.

Moderna, Immatics agree to a cancer-focused collab that could top $1.7B
Moderna, Immatics agree to a cancer-focused collab that could top $1.7B
Jack O'Brien
September 11, 2023
11:06 am

As part of the deal, Immatics will receive $120 million upfront from Moderna and is eligible to receive milestone payments that could top $1.7 billion.

  • From Our Partners